Clinical trial
LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small…
NCT00005858 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00005858 |
|---|---|
| Title | LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer |
| Official title | Phase I Study of LMB-9, a Recombinant Disulfide Stabilized Anti-Lewis Y Immunotoxin Admistered by Continuous Infusion |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer |
| Intervention type | Biological |
| Interventions | LMB-9 immunotoxin |
| Enrollment | 25 |
| Start date | Apr 1, 2000 |
| Primary completion | Dec 1, 2003 |
| Completion | Dec 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 4, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: